The accuracy of distinguishing relapsing–remitting multiple sclerosis from aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein antibody-associated disease can be achieved with high precision using cortical lesions, central vein sign, and optic nerve markers. When serologic testing for relapsing-remitting multiple sclerosis (RRMS), aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder (AQP4-NMOSD), and myelin oligodendrocyte glycoprotein...